# The Cooper Companies, Inc. (COO)

> Source: Nexqual · https://nexqual.com/COO · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, The Cooper Companies, Inc. (COO), nexqual.com/COO" · informational, not investment advice.

**Price:** USD 61.65 (+4.54% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 58.97 · day 59.27–61.66 · 52w 51.01–89.83 · market cap $11.7B · NMS

## Key facts
- Last four reported quarters (through Jul 31, 2026): revenue $4.24B, net income $570M (13.5% margin), free cash flow $678M (SEC filings).
- Valuation: P/E 20.6x (avg 47.9x at the last 3 fiscal year-ends), EV/EBITDA 16.9x, net debt $2.39B.
- 2 of 80 tracked superinvestors hold COO (13F, Q2 2026): 1 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $1.9M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 2.59 on a 1–5 scale) (17 analysts), mean target USD 65.8 (range 58–75).
- Total return with dividends: 1Y -17.3% vs S&P 500 +14.9%; 5Y -40.9% vs S&P 500 +80.3%.
- Next earnings: 2026-09-09, EPS estimate USD 1.07, revenue estimate $1.07B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.92B | $3.31B | $3.59B | $3.90B | $4.09B | $4.24B |
| Gross profit | $1.96B | $2.14B | $2.36B | $2.60B | $2.68B | — |
| Operating income | $506M | $508M | $533M | $706M | $683M | $544M |
| Net income | $2.94B | $386M | $294M | $392M | $375M | $570M |
| EPS (diluted) | $14.79 | $1.94 | $1.48 | $1.96 | $1.87 | — |
| Free cash flow | $524M | $450M | $215M | $288M | $434M | $678M |
| Gross margin | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% | — |
| Operating margin | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% | 12.8% |
| Net margin | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% | 13.5% |
| Revenue growth | +20.2% | +13.2% | +8.6% | +8.4% | +5.1% | — |
| Cash + short-term investments | $95.9M | $138M | $121M | $108M | $111M | — |
| Total debt | $1.48B | $2.76B | $2.57B | $2.58B | $2.51B | — |
Fiscal years end Oct. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 31, 2026)
P/E 20.6x · P/S 2.8x · EV/EBITDA 16.9x · EV/Sales 3.3x · P/FCF 17.3x · P/B 1.4x · FCF yield 5.78% · Earnings yield 4.86% · Buyback yield (TTM) 5.49% · Net debt $2.39B · EV $14.1B
P/E at fiscal year-ends: Oct 2025 37.3x, Oct 2024 53.5x, Oct 2023 52.8x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold COO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds |  | 0.23% | $1.7M | Reduced -8.4% |
| Bill Nygren | Oakmark Funds | 0.07% | $55.0M | New position |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
4 purchases, $1.9M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-16 | Kurzius Lawrence Erik | Director | 10,000 | $549K | 54.93 | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-11…2026-09-14 | Rosebrough Walter M Jr | Director | 10,000 | $542K | 54.16 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-14 | Kurzius Lawrence Erik | Director | 10,000 | $539K | 53.91 | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-11 | Keel Paul A | Director | 4,701 | $250K | 53.18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.59 on a 1–5 scale), 17 analysts; mean target USD 65.8 (low 58, high 75).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $60 |
| 2026-09-15 | Needham | Reiterated | Buy | $73 |
| 2026-09-11 | Mizuho | Target lowered | Outperform | $85 → $75 |
| 2026-09-10 | William Blair | Downgrade | Outperform → Market Perform |  |
| 2026-09-10 | Wells Fargo | Target lowered | Equal-Weight | $66 → $61 |
| 2026-09-10 | Stifel | Target lowered | Buy | $85 → $70 |
| 2026-09-10 | Citigroup | Target lowered | Neutral | $80 → $60 |
| 2026-09-10 | Piper Sandler | Downgrade | Overweight → Neutral | $86 → $59 |
| 2026-09-10 | JP Morgan | Target lowered | Neutral | $71 → $58 |
| 2026-09-10 | UBS | Target lowered | Neutral | $75 → $66 |
| 2026-09-10 | B of A Securities | Downgrade | Buy → Neutral | $80 → $65 |
| 2026-09-10 | Baird | Downgrade | Outperform → Neutral | $85 → $61 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -17.3% | -40.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -17.3% | -9.9% |
| Volatility (annualized) | 32.5% | 31.8% |
| Max drawdown | -36.8% (Jan 2026→Sep 2026) | -51.2% (Sep 2024→Sep 2026) |

## Peers (Medical Instruments & Supplies)
RGEN (Repligen Corporation) USD 178.71 -0.72% · AVTR (Avantor, Inc.) USD 17.15 -0.64% · ALGN (Align Technology, Inc.) USD 155.51 +2.74% · BAX (Baxter International Inc.) USD 25.65 +3.85% · SOLV (Solventum Corporation) USD 87.45 +0.90% · ATR (AptarGroup, Inc.) USD 128.1 +1.97%

## More
Full page: https://nexqual.com/COO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Coopervision | $717.0M | 67.2% | -0.2% | $205.5M | 28.7% |
| Coopersurgical | $349.2M | 32.8% | +2.1% | $41.1M | 11.8% |
| Corporate costs (not allocated) | — | — | — | -$24.6M | — |
| Total revenue | $1.07B | 100% | — | $222.0M | 20.8% |

## Revenue by product line (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Toric & Multifocal | $363.8M | 34.1% | +1.4% |
| Sphere Other | $353.2M | 33.1% | -1.8% |
| Office & Surgical | $208.0M | 19.5% | +1.6% |
| Fertility | $141.2M | 13.2% | +3.0% |
| Total revenue | $1.07B | 100% | — |

## Revenue by region (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $519.5M | 48.7% | +0.6% |
| Europe | $357.5M | 33.5% | +4.2% |
| Rest of world | $189.2M | 17.7% | -5.9% |
| Total revenue | $1.07B | 100% | — |

## Company outlook (8-K filed 2026-09-09)

- "The Company updated its fiscal year 2026 financial guidance."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-10-31) | $1.07 | $1.20 | -10.8% | $1.07B | 16 |
| Next quarter (ends 2027-01-31) | $1.10 | $1.17 | -5.5% | $1.05B | 10 |
| Current fiscal year (ends 2026-10-31) | $4.53 | $4.63 | -2.1% | $4.24B | 17 |
| Next fiscal year (ends 2027-10-31) | $4.69 | $5.00 | -6.2% | $4.41B | 17 |